Trial Search Results

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

This study will involve treatment with an experimental drug called SNX-5422 mesylate (referred to simply as SNX-5422). The main purpose of this study is to determine the highest dose of SNX-5422 when combined with daily everolimus that can be tolerated when SNX-5422 is given once every other day for 21 days followed by a 1-week period (7 days) without study drug. Everolimus will be taken daily for 28 days. Other goals of this study are to study its side effects, to measure its possible effects on the tumor, and to further study how this drug works.

Stanford is currently not accepting patients for this trial.

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting